干扰素治疗对慢性丙型肝炎患者听力的影响。
Effect of interferon treatment on hearing of patients with chronic hepatitis C.
机构信息
Department of ENT, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
出版信息
Saudi J Gastroenterol. 2011 Mar-Apr;17(2):114-8. doi: 10.4103/1319-3767.77240.
BACKGROUND/AIM: Some reports in the literature have linked interferon therapy for the treatment of hepatitis C (HCV) with hearing loss. The aim of this study has been to examine the effects of interferon therapy on hearing of patients treated for HCV.
PATIENTS AND METHODS
Patients were recruited according to preset inclusion criteria from two centers. All patients received standard dose pegylated interferon (PEG-IFN a-2b or a-2a) plus ribavirin (RBV). All patients had pure-tone audiometry (PTA), tympanogram and distortion-product otoacoustic emission (DPOAE) before treatment, three months after initiation of treatment, and three months after completion of treatment.
RESULTS
Twenty one patients were prospectively recruited. The mean age was 45.7 years. The male to female ratio was 1.1:1. The mean PTA was 15.9 ± 5.3 before treatment, 17.4 ± 6.1 during treatment and 16.5 ± 5.1 after treatment. The differences between pre and mid, pre and post, as well as mid and post were not significantly different (P>0.05) in all audiological assessments.
CONCLUSIONS
Our results indicate that PEG-IFN\RBV therapy does not have any impact on the hearing thresholds of patients with HCV.
背景/目的：一些文献报道将干扰素治疗丙型肝炎（HCV）与听力损失联系起来。本研究旨在检查干扰素治疗对接受 HCV 治疗的患者听力的影响。
患者和方法
根据两个中心的预设纳入标准招募患者。所有患者均接受标准剂量聚乙二醇干扰素（PEG-IFN a-2b 或 a-2a）加利巴韦林（RBV）治疗。所有患者在治疗前、治疗开始后 3 个月和治疗结束后 3 个月均进行纯音听阈测试（PTA）、鼓室图和畸变产物耳声发射（DPOAE）检查。
结果
21 例患者前瞻性入组。平均年龄为 45.7 岁。男女比例为 1.1:1。治疗前 PTA 平均为 15.9 ± 5.3dB，治疗期间为 17.4 ± 6.1dB，治疗结束后为 16.5 ± 5.1dB。所有听力评估中，治疗前与治疗中期、治疗前与治疗后以及治疗中期与治疗后之间的差异均无统计学意义（P>0.05）。
结论
我们的结果表明，PEG-IFN\RBV 治疗对 HCV 患者的听力阈值没有影响。
Zotero 插件